Compelling preclinical data in models of both GBA1-PD and idiopathic PD, demonstrating a disease-modifying effect after ...

The drug – a selective muscarinic M4 receptor positive allosteric modulator (PAM) – is designed to have limited effect on dopamine neurotransmission, a mechanism thought to contribute to ...

Domain Therapeutics (“Domain” or “the Company”), the GPCR experts harnessing deep receptor biology to develop breakthrough treatments for patients, today announces it has nominated and is progressing ...

First patient dosed in Phase II OCULE-01 study with roginolisib, an allosteric modulator of PI3Kd The European Medicines Agency (EMA) has granted Orphan Drug Designation for roginolisib for ...

First patient dosed in Phase II OCULE-01 study with roginolisib, an allosteric modulator of PI3Kδ The European Medicines Agency (EMA) has granted Orphan Drug Designation for roginolisib for treatment ...